BackNu-Med Plus Overview

Nu-Med Plus EBIT

Latest ebit for NUMD: $-56K, below the sector sector average of $2.4T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$22.56K
↓ 116.49% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

-$55.54K
↑ 0.51% YoY

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Nu-Med Plus (NUMD) FAQ

The latest EBIT for NUMD is $-56K as of June 2026. That compares with $-56K in the prior-year period — up 0.5% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside Nu-Med Plus's historical trend and sector peers before judging valuation or financial health.

Over the past year, NUMD's EBIT moved from $-56K to $-56K — a 0.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nu-Med Plus's operating scale or balance-sheet position.

Against its sector companies, NUMD currently prints $-56K for EBIT, while the sector average sits near $2.4T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Nu-Med Plus's growth, margins, and balance sheet.

A EBIT figure of $-56K for NUMD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.

After noting NUMD's EBIT ($-56K), review year-over-year change from $-56K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.